Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy

Area of Science:

• Nephrology
• Immunology
• Biomarker Research

Background:

• Immunoglobulin A nephropathy (IgAN) presents a significant clinical challenge due to the variable rate of kidney function decline.
• Accurate prediction of disease progression and identification of patients who will benefit from novel therapies are currently limited.

Purpose of the Study:

• To review existing demographic, clinical, and histopathologic prognostic markers for IgAN.
• To highlight the urgent need for noninvasive, validated markers for patient selection and monitoring.
• To discuss emerging research areas for novel predictive and prognostic markers in IgAN.

Main Methods:

• Review of current literature on prognostic markers in IgAN.
• Summary of established clinical and histopathologic tools.
• Discussion of ongoing research into novel biomarkers.

Main Results:

• Current markers, including the International IgAN Prediction Tool, rely heavily on kidney biopsy histology and standard clinical data.
• Few noninvasive markers exist for longitudinal monitoring of treatment efficacy.
• Promising research areas include complement activation, gut microbiota, microRNAs, imaging, AI, and fibrosis markers.

Conclusions:

• There is a critical need for robust, clinically practical, noninvasive biomarkers to improve IgAN prognosis.
• Advancements in biomarker research, particularly in complement activation, are crucial for personalized treatment strategies.
• Translating novel predictive and prognostic markers into clinical utility is essential for better patient care in IgAN.